Virpax Pharmaceuticals (VRPX) Peer Comparison
$0.00
$-0.22
(-99.95%)
As on 16-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Edit
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 17,335 | 16,399 | 13,906 | 12,349 |
Revenue ($ Mln) |
-- | 1,054 | 2,782 | 2,436 | 1,284 |
Net Profit ($ Mln) |
-12.07 | 755.85 | 491.50 | 860.62 | -325.10 |
Net Margin (%) |
-- | 71.69 | 17.67 | 35.33 | -25.32 |
RoE (%) |
-2,364.82 | -- | 110.09 | 42.98 | -57.72 |
Price to Earnings |
-- | 20.24 | 34.46 | 17.65 | -- |
Price-To-Book |
0.48 | 10.29 | 37.52 | 7.54 | 23.52 |
Income Statement ($ Mln)
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 363.64 | 2,109.05 | 2,168.70 | 180.13 |
|
Cost of Revenue
|
-- | 44.26 | 1,452.75 | 76.22 | 6.23 |
|
Gross Profit
|
-- | 319.38 | 656.31 | 2,092.49 | 173.90 |
|
Operating Expenses
|
12.08 | 598.15 | 209.44 | 1,487.87 | 671.78 |
|
Operating Profit (EBIT)
|
-12.08 | -278.76 | 446.87 | 604.62 | -497.88 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-12.07 | -373.24 | 475.92 | 681.64 | -465.89 |
|
Provision for Tax
|
-- | 4.84 | 71.54 | 160.37 | -465.89 |
|
Profit after Tax (Net Income)
|
-12.07 | -378.08 | 404.39 | 521.27 | -465.89 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-0.91 | -105.71 | 825.55 | 2,244.20 | 754.38 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 377.34 | 170.77 | 299.72 | 118.59 |
|
Current Liabilities
|
2.47 | 907.86 | 1,104.55 | 403.77 | 169.28 |
|
Total Liabilities
|
1.56 | 1,179.50 | 2,100.87 | 2,947.69 | 1,042.25 |
Assets ($ Mln)
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 118.63 | 1,071.64 | 1,480.11 | 9.32 |
|
Current Assets
|
1.56 | 1,060.86 | 1,029.23 | 1,467.58 | 1,032.93 |
|
Total Assets
|
1.56 | 1,179.50 | 2,100.87 | 2,947.69 | 1,042.25 |
|
Total Debt*
|
-- | 856.62 | 149.52 | 190.82 | 119.57 |
|
Net Current Assets
|
-0.91 | 153.00 | -75.32 | 1,063.81 | 863.65 |
Cashflow ($ Mln)
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-16,712.90 | -306.20 | 608.82 | 699.97 | -455.57 |
|
Cash Flow from Investing Activities
|
-- | 6.88 | -28.31 | -116.78 | -274.39 |
|
Cash from Financing Activities
|
9,084.45 | 443.93 | -154.01 | -628.81 | 735.06 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2,364.82 | -56.08 | 48.25 | 21.32 | -66.72 |
|
ROE (%)
|
-2,364.82 | 300.78 | 58.42 | 23.13 | -80.35 |
|
ROA (%)
|
-215.80 | -37.71 | 21.52 | 17.70 | -55.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -103.97 | 19.17 | 24.04 | -258.64 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.36 | 0.12 | 0.18 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
20.56 | 21.47 | 42.99 | 150.89 | -24.69 |
|
EPS Growth (%)
|
0.78 | 0.26 | 0.42 | 1.79 | -0.12 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.13 | -21.77 | 26.30 | 18.00 | -14.52 |
|
Price / Book Value
|
-1.77 | -77.86 | 12.88 | 4.18 | 8.97 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
126.34 | -29.40 | 20.03 | 11.77 | -13.24 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -8.10 | 0.18 | 0.09 | 0.16 |
|
Short term debt to equity ratio
|
-- | -4.65 | 0.03 | 0.01 | 0.00 |
|
Current Ratio
|
0.63 | 1.17 | 0.93 | 3.63 | 6.10 |
|
Quick Ratio
|
-- | 0.84 | -- | 3.58 | 5.90 |
|
Interest Coverage
|
-146.40 | -4.70 | 19.04 | -- | -30.76 |
Operating Efficiency Ratios
| Virpax Pharmaceuticals (VRPX) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 45.73 | 14.06 | 12.24 | 29.88 |
|
Asset Turnover
|
0.00 | 0.36 | 1.12 | 0.74 | 0.21 |
|
Receivable days
|
-- | 101.52 | 51.51 | 42.34 | 54.57 |
|
Inventory Days
|
-- | 2,081.92 | 0.00 | 95.15 | 998.18 |
|
Payable days
|
-- | 787.97 | 8.10 | 172.42 | 2,099.03 |
|
Cash Conversion Cycle
|
-- | 1,395.47 | 43.41 | -34.93 | -1,046.28 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
